1Knodell RG,Ishak KG,Black WC,et al.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chromic active hepatitis[J].Hepatology,1981,1:431～435.
2Suzuki Y,Kumada H,Ikeda K,et al.Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection[J].J Hepatol,1999,30:743～748.
3Manns MP,McHutchison JG,Gordon SC,et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomized trial[J].Lancet,2001,358:958～965.
4Fired MW.Side effects of therapy for hepatitis C and their management[J].Hepatology,2002,36:237～244.
5Zenzem S,Feinman SV,Resenack J,et al.Peginterferon Alfa-2a in Patients with Chronic Hepatitis B[J].N Engl J Med,2000,343:1 666～1 672.
6[1]Xu ZX, Hoffman J, Patel I, et al. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon ( PEG-IFN ) and interferon α-2a(IFNα-2a)to healthy subjects[J]. Hepatology, 1998,28(4 pt 2):702A.
7[2]Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG)and moiety optimizes the pharmacokinetics(PK) of pegIFNα-2a( PEG-IFN)and may explain its enhanced efficacy in chronic hepatitis C (CHC) [ J ]. Hepatology,1999,30(4 pt 2): 190A.
8[3]Modi MW, Fried M, Reindollar RW, et al. The pharmacokinetic behavior of pegylated (40kDa) interferon alfa-2a ( PEGASYS TM)in chronic hepatitis C patients after multiple dosing[J]. Hepatology,2000,32 (4 pt 2) :394A.
9[4]Perry CM, Jarvis B. Peginterferon α-2a (40kD):a review of its use in the management of chronic hepatitis C[ J ]. Drugs, 2001,61:2263 - 2288.
10[5]Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a [ J ]. Ann Pharmacother, 2002,36: 933 - 935.
